Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial
Journal of Clinical Oncology · 10.02.2024 · 42 (5) · 500-506
DOI: 10.1200/jco.23.01208 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2024. Verfasst von Floris S Verheij und 42 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Adenocarcinoma, Rectal Neoplasms. Die Arbeit wurde bisher 402-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. To assess long-term risk of local tumor regrowth, we report updated organ preservation rate and oncologic outcomes of the OPRA trial (ClinicalTrials.gov identifier: NCT02008656 ). Patients with stage II/III rectal cancer were randomly assigned to receive induction chemotherapy followed by chemoradiation (INCT-CRT) or chemoradiation followed by consolidation chemotherapy (CRT-CNCT). Patients who achieved a complete or near-complete response after finishing treatment were offered watch-and-wait (WW). Total mesorectal excision (TME) was recommended for those who achieved an incomplete response. The primary end point was disease-free survival (DFS). The secondary end point was TME-free survival. In total, 324 patients were randomly assigned (INCT-CRT, n = 158; CRT-CNCT, n = 166). Median follow-up was 5.1 years. The 5-year DFS rates were 71% (95% CI, 64 to 79) and 69% (95% CI, 62 to 77) for INCT-CRT and CRT-CNCT, respectively ( P = .68). TME-free survival was 39% (95% CI, 32 to 48) in the INCT-CRT group and 54% (95% CI, 46 to 62) in the CRT-CNCT group ( P = .012). Of 81 patients with regrowth, 94% occurred within 2 years and 99% occurred within 3 years. DFS was similar for patients who underwent TME after restaging (64% [95% CI, 53 to 78]) and patients in WW who underwent TME after regrowth (64% [95% CI, 53 to 78]; P = .94). Updated analysis continues to show long-term organ preservation in half of the patients with rectal cancer treated with total neoadjuvant therapy. In patients who enter WW, most cases of tumor regrowth occur in the first 2 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
- Division of Colon and Rectal Surgery, Department of Surgery, University of South Florida, Tampa, FL.
- Division of General Surgery, Department of Surgery, University of Vermont, Burlington, VT.
- Department of Medicine, Comprehensive Cancer Center, University of Chicago, Chicago, IL.
ORCID-Profile: Floris S Verheij, Sabrina T Lin, Li-Xuan Qin, Jonathan B Yuval, Jin K Kim, Richard F Dunne, Jorge Marcet, Blase Polite, Daniel O Herzig, David Liska, Charles Ternent, Andrew L Coveler, Madhulika G Varma, Joseph C Carmichael, John Krauss, José G Guillem, Karyn A Goodman, Neil H Segal, Andrea Cercek, Rona Yaeger, Iris H Wei, Emmanouil P Pappou, Martin R Weiser, Philip B Paty, J Joshua Smith, Abraham J Wu, Marc J Gollub, Leonard B Saltz, Julio Garcia-Aguilar
Förderung
- NCI NIH HHS
Zitieren
APA
Verheij, F. S., Omer, D. M., Williams, H., Lin, S. T., Qin, L. X., Buckley, J. T., Thompson, H. M., Yuval, J. B., Kim, J. K., Dunne, R. F., Marcet, J., Cataldo, P., Polite, B., Herzig, D. O., Liska, D., Oommen, S., Friel, C. M., Ternent, C., Coveler, A. L., …, & Garcia-Aguilar, J. (2024). Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. Journal of Clinical Oncology, 42(5), 500-506. https://doi.org/10.1200/jco.23.01208
Vancouver
Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. Journal of Clinical Oncology. 2024;42(5):500-506. doi:10.1200/jco.23.01208
BibTeX
@article{Verheij2024,
author = {Verheij, Floris S and Omer, Dana M and Williams, Hannah and Lin, Sabrina T and Qin, Li-Xuan and Buckley, James T and Thompson, Hannah M and Yuval, Jonathan B and Kim, Jin K and Dunne, Richard F and Marcet, Jorge and Cataldo, Peter and Polite, Blase and Herzig, Daniel O and Liska, David and Oommen, Samuel and Friel, Charles M and Ternent, Charles and Coveler, Andrew L and Hunt, Steven and Gregory, Anita and Varma, Madhulika G and Bello, Brian L and Carmichael, Joseph C and Krauss, John and Gleisner, Ana and Guillem, José G and Temple, Larissa and Goodman, Karyn A and Segal, Neil H and Cercek, Andrea and Yaeger, Rona and Nash, Garrett M and Widmar, Maria and Wei, Iris H and Pappou, Emmanouil P and Weiser, Martin R and Paty, Philip B and Smith, J Joshua and Wu, Abraham J and Gollub, Marc J and Saltz, Leonard B and Garcia-Aguilar, Julio},
title = {Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {5},
pages = {500--506},
doi = {10.1200/jco.23.01208}
}
EUVIMED